A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas


I'm Interested

Trial ID: NCT05475925


This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymphomas

Official Title

A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

Stanford Investigator(s)

Youn H Kim, MD
Youn H Kim, MD

The Joanne and Peter Haas, Jr., Professor for Cutaneous Lymphoma Research and Professor, by courtesy, of Medicine (Oncology)


Inclusion Criteria (All Subjects):

   1. ≥18 years of age.

   2. Able to understand and comply with protocol-required study procedures and voluntarily
   sign a written informed consent document.

   3. Sufficient key organ performance and coagulation.

   4. Female subjects of childbearing potential (postmenarcheal, has an intact uterus and at
   least one ovary, and is <1 year postmenopausal) must agree to use a highly effective
   method of contraception from enrollment through at least 12 months after last dose of

   5. Male subjects must agree to use acceptable effective method(s) of contraception.

   Subjects with LGLL must also meet inclusion criteria 6 and 7.

   6. Must have discontinued at least one prior line of systemic therapy.

   7. Additional immunophenotypic criteria must be met.

   Disease-specific Inclusion Criteria (Cytotoxic Lymphomas):

   Subjects with cytotoxic lymphomas must also meet inclusion criteria 8,9, and 10.

   8. Subjects must have failed at least two prior systemic regimens.

   9. Availability of post-progression tissue sample or willingness to consent to a baseline

10. Histologically confirmed diagnosis of a cytotoxic lymphoma by a hematopathologist
   (according to the WHO 2016 classification [Swerdlow 2016]).

11. For Part A only, evaluable disease is acceptable.

12. For Part B2 only:

Subjects must have radiographically measurable disease to be assessed by Lugano criteria.
Subjects with primary cutaneous variants must have at least 1 measurable lesion that is
evaluable using the Olsen criteria (Olsen 2021) or leukemic involvement that can be
evaluated using a modified TPLL response criteria (Staber 2019).

Subjects with hepatosplenic disease or other variants that do not have measurable disease
by Lugano criteria (Cheson 2014) may be eligible upon discussion with the Medical Monitor
if they have identifiable leukemic involvement in BM or peripheral blood (meeting the CD8+
cytotoxic phenotype definition) that can be evaluated for response using a modified TPLL
response criteria (Staber 2019), or skin involvement that can be evaluated using Olsen
criteria (Olsen 2021).

Exclusion Criteria:

Disease-specific Exclusion Criteria; LGLL and ANKL:

   1. A reactive LGL lymphocytosis to a viral infection or LGL associated with
   myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).

   The following exclusion criteria apply to all subjects:

   2. Active systemic infection or severe localized infection requiring systemic
   antibiotics, antivirals or antifungals.

   3. Active or suspected malignant central nervous system involvement.

   4. Life-threatening, severe complications of malignancy (e.g., uncontrolled bleeding,
   pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation).

   5. Active known second malignancy.

   6. Infection with human immunodeficiency virus (HIV) type 1 or 2 (HIV-1 or HIV-2).

   7. Hepatitis B infection (hepatitis B virus surface antigen [HBsAg] positive), or
   hepatitis C (hepatitis C virus [HCV] antibody positive, confirmed by HCV ribonucleic
   acid). Subjects with HCV with undetectable virus after treatment are eligible.

   8. History of clinically significant cardiac disease or congestive heart failure greater
   than New York Heart Association (NYHA) Class II.

   9. Use of systemic corticosteroids (e.g., >5 mg/day prednisone or equivalent for subjects
   with LGL leukemia (subjects on 20 mg prednisone or equivalent to treat LGL leukemia
   must be weaned within 28 days post C1D1 to 5 mg) and >10 mg/day prednisone or
   equivalent for subjects with cytotoxic lymphoma) within 15 days (except for
   prophylaxis for radiodiagnostic contrast reactions), or other non-biological
   immunosuppressive drugs within 15 days, prior to C1D1. Patients on stable prednisone
   ≤10 mg for documented rheumatologic/autoimmune conditions are exempted from this

10. Any condition requiring hormonal therapy (except for contraception, hormone
   replacement therapy and hormonal prophylaxis for a prior malignancy).

11. Any other medical or psychiatric condition, or laboratory abnormality that would
   increase the risk associated with study participation, in the opinion of the
   Investigator or Medical Monitor.

12. Toxicities from previous anticancer therapies must have resolved to baseline levels or
   to Grade 1 (except for alopecia, peripheral neuropathy, or hematologic parameters
   meeting inclusion criteria).

13. Autologous HSCT within 40 days of C1D1, allogeneic HSCT within 90 days

14. Any immunosuppressive therapy for GVHD for subjects who are post allogeneic HSCT.

15. Major surgery within 28 days of C1D1 (requires more than local anesthesia or plexus


drug: DR-01


I'm Interested

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Ellen Kim

New Trial Alerts